千金药业(600479) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 960,198,380.73, representing a year-on-year increase of 0.78%[5] - The net profit attributable to shareholders for the same period was CNY 43,906,688.63, reflecting a growth of 9.83% compared to the previous year[5] - The basic earnings per share for Q1 2023 was CNY 0.1021, which is an increase of 9.78% year-on-year[6] - Net profit for Q1 2023 reached CNY 56,747,393.26, representing a 11.8% increase from CNY 51,053,482.14 in Q1 2022[22] - Earnings per share (EPS) for Q1 2023 was CNY 0.1021, up from CNY 0.0930 in Q1 2022, indicating a growth of 11.7%[22] - Operating profit for Q1 2023 was CNY 66,059,069.40, an increase of 10.0% compared to CNY 60,011,882.13 in Q1 2022[22] - The total comprehensive income for Q1 2023 was CNY 56,747,616.03, compared to CNY 51,057,662.72 in Q1 2022, indicating a growth of 11.1%[22] Cash Flow - The net cash flow from operating activities was negative at CNY -194,039,475.06, a decline of 117.95% compared to the previous year[5] - In Q1 2023, the company reported cash inflows from operating activities of CNY 892,443,008.01, a slight increase from CNY 888,763,769.19 in Q1 2022[23] - The net cash flow from operating activities was negative at CNY -194,039,475.06, compared to CNY -89,031,314.87 in the same period last year[23] - Cash inflows from investment activities totaled CNY 673,552,699.43, up from CNY 454,306,953.47 in Q1 2022[24] - The net cash flow from investment activities increased significantly to CNY 353,581,904.39, compared to CNY 105,206,951.54 in the previous year[24] - The company recorded cash inflows from financing activities of CNY 439,200.00, a decrease from CNY 48,590,000.00 in Q1 2022[24] - The net cash flow from financing activities was minimal at CNY 10,325.86, down from CNY 48,036,077.26 in the same quarter last year[24] - The ending balance of cash and cash equivalents increased to CNY 1,263,103,574.11, compared to CNY 574,712,986.35 at the end of Q1 2022[24] - The company’s total cash inflow from sales of goods and services was CNY 845,525,998.14, slightly higher than CNY 833,670,513.80 in Q1 2022[23] - Total cash outflows from operating activities were CNY 1,086,482,483.07, compared to CNY 977,795,084.06 in the previous year[23] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to CNY 4,532,287,499.46, down 1.94% from the end of the previous year[6] - As of March 31, 2023, the total current assets amounted to ¥3,429,983,040.81, a decrease of 2.38% from ¥3,513,491,527.41 on December 31, 2022[15] - The total assets decreased to ¥4,532,287,499.46 from ¥4,621,975,680.77, indicating a decline of 1.93%[16] - Total liabilities decreased to CNY 1,655,459,691.84 in Q1 2023 from CNY 1,805,690,959.18 in Q1 2022, a reduction of approximately 8.3%[21] - The company reported a decrease in total non-current liabilities to CNY 98,930,438.54 in Q1 2023 from CNY 108,469,095.61 in Q1 2022, a decline of approximately 8.5%[21] - Total equity increased to CNY 2,876,827,807.62 in Q1 2023 from CNY 2,816,284,721.59 in Q1 2022, reflecting a growth of about 2.1%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,602[12] Other Financial Metrics - The company's weighted average return on equity was 1.96%, an increase of 0.12 percentage points from the previous year[6] - Research and development expenses for Q1 2023 were CNY 23,884,290.27, a decrease of 5.1% from CNY 25,165,661.29 in Q1 2022[21] - Other income for Q1 2023 was CNY 6,753,939.61, significantly higher than CNY 3,157,591.09 in Q1 2022, marking an increase of 114.3%[21] - The company reported a significant increase in other receivables by 314.02%, primarily due to increased advances and guarantees[10] - The company experienced a 69.44% decrease in trading financial assets, mainly due to the redemption of bank structured deposits[10] - The company received government subsidies that contributed to a 113.90% increase in other income[10] - The company reported a significant increase in other receivables, which reached ¥115,239,579.50, compared to ¥27,834,261.03, marking a growth of 313.36%[15] - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - Short-term borrowings decreased to ¥51,539,744.30 from ¥58,131,110.09, a reduction of 10.00%[16] - Accounts payable increased to ¥379,080,960.03, up 19.14% from ¥318,206,420.96[16] - Other payables rose to ¥460,387,086.60, an increase of 19.22% from ¥386,193,457.69[16]